The information on this page pertains to selected congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas. Congress materials may include information for which the product is not approved and/or inconsistent with the product uses described in the local Prescribing Information. Pfizer does not suggest or recommend the use of Pfizer Products in any manner other than as described in the local approved Prescribing Information. Where the product is not marketed in Hong Kong, all information in this document is off-label.
September 8, 2021 IMW 2021 Hematology
December 11, 2021 ASH 2021 Hematology
December 12, 2021 ASH 2021 Hematology
A Phase I/II Study of Bosutinib in Pediatric Patients with Resistant/Intolerant or Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia, Study ITCC (Innovative Therapies for Children with Cancer European Consortium) 054 and COG (Children's Oncology Group Consortium) AAML1921: Results from the Phase I Trial in Resistant/Intolerant Patients
April 10, 2022 AACR 2022 Hematology